BioLineRx annual net debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioLineRx Net Debt Growth & History (BLRX)
BioLineRx's net debt was $2.4M for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.4M | $6.8M | — |
| 2024 | 2024-12-31 | −$4.4M | −$5.1M | — |
| 2023 | 2023-12-31 | $708,000 | $7.6M | — |
| 2022 | 2022-12-31 | −$6.9M | $1.4M | — |
| 2021 | 2021-12-31 | −$8.3M | $808,000 | — |
| 2020 | 2020-12-31 | −$9.1M | −$14.3M | — |
| 2019 | 2019-12-31 | $5.2M | −$2.0M | −28.43% |
| 2018 | 2018-12-31 | $7.2M | $12.1M | — |
| 2017 | 2017-12-31 | −$4.9M | −$2.7M | — |
| 2016 | 2016-12-31 | −$2.1M | — | — |
BioLineRx quarterly net debt
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.3M | $4.6M | — |
| Q1 2026 | 2026-03-31 | $6.6M | $1.9M | +39.52% |
| Q4 2025 | 2025-12-31 | $2.4M | $6.8M | — |
| Q3 2025 | 2025-09-30 | $3.5M | — | — |
| Q2 2025 | 2025-06-30 | −$1.3M | −$4.1M | — |
| Q1 2025 | 2025-03-31 | $4.7M | — | — |
| Q4 2024 | 2024-12-31 | −$4.4M | −$5.1M | — |
| Q2 2024 | 2024-06-30 | $2.8M | $7.9M | — |
| Q4 2023 | 2023-12-31 | $708,000 | $7.6M | — |
| Q2 2023 | 2023-06-30 | −$5.1M | $6.3M | — |
| Q4 2022 | 2022-12-31 | −$6.9M | $1.4M | — |
| Q2 2022 | 2022-06-30 | −$11.4M | $869,000 | — |
| Q4 2021 | 2021-12-31 | −$8.3M | $808,000 | — |
| Q2 2021 | 2021-06-30 | −$12.3M | −$11.4M | — |
| Q4 2020 | 2020-12-31 | −$9.1M | −$14.3M | — |
| Q2 2020 | 2020-06-30 | −$826,000 | −$17,000 | — |
| Q4 2019 | 2019-12-31 | $5.2M | −$2.0M | −28.43% |
| Q2 2019 | 2019-06-30 | −$809,000 | $4.9M | — |
| Q4 2018 | 2018-12-31 | $7.2M | $12.1M | — |
| Q2 2018 | 2018-06-30 | −$5.7M | — | — |
| Q4 2017 | 2017-12-31 | −$4.9M | — | — |
BioLineRx net debt trends
Over the last five fiscal years, BioLineRx's net debt increased from −$9.1M to $2.4M, a change of $11.6M. The latest reported quarter, Q2 2026, shows $3.3M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗